Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine
kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently …

3005 Background: SHP2 transduces signals from activated receptor tyrosine kinases to
downstream pathways including MAPK. TNO155 is a selective, allosteric, oral inhibitor of …

SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays …

Rationally targeted therapies have transformed cancer treatment, but many patients develop
resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an …

Background: Mutations in KRAS are among the most common aberrations in cancer.
However, despite considerable research efforts, KRAS remains a challenging therapeutic …

FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …

The nonreceptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) integrates
growth and differentiation signals from receptor tyrosine kinases (RTKs) into the …

Src homology 2 domain-containing phosphatase (SHP2) is a phosphatase that mediates
signaling downstream of multiple receptor tyrosine kinases (RTK) and is required for full …

Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …

Protein tyrosine phosphatase SHP2 mediates RAS-driven MAPK signaling and has
emerged in recent years as a target of interest in oncology, both for treating with a single …